ArticleDiscover oncology2026
Prognostic model of immune -related immune models of ANLN single gene based on TCGA lung adenocarcinoma database.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anillin (ANLN) encodes one actin-binding protein tightly associated with cell growth, cytokinesis, and migration. The present work focused on exploring differential ANLN expression in lung adenocarcinoma (LUAD). We built an ANLN-related immune prognostic model and verified its feasibility. R and Bioconductor -related software were employed for differential, survival, univariate as well as multivariate analysis. The significance level was P < 0.05. ANLN expression within LUAD tissues was increased compared with non-carcinoma tissues, and ANLN up-regulation in LUAD was associated with poor prognosis. CD8 + T cells showed positive relation to activated CD4 + T cells in LUAD. M2 macrophage abundance was inversely correlated with plasma cell expression. ANLN expression was associated with 17 lymphocytes, 33 immunostimulators, and 13 immunoinhibitors. ANLN-related immunomodulatory genes were mainly involved in cytokine activity, receptor ligand activity, cytokine receptor binding, and tumor necrosis factor receptor binding, and regulated signaling pathways like NF-κB and JAK–STAT pathways. LASSO regression was used to establish an immune risk model. In addition, model prediction performance and feasibility were validated through univariate analysis, multivariate analysis, survival analysis, and ROC curve analysis. Crucially, in vitro experiments demonstrated that ANLN knockdown significantly inhibited the proliferation and migration of A549 and H1299 cells. Mechanistically, ANLN depletion led to the downregulation of NF-κB-related inflammatory cytokines (IL6, CXCL8, and TNF), suggesting a potential role in modulating the tumor immune microenvironment. In conclusion, The ANLN gene is a candidate biomarker for predicting LUAD prognosis, and the constructed risk model may serve as an independent predictor of LUAD prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.